Avoro Capital Advisors LLC - 12 May 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Reporting relationship: Director, Other*, 10%+ Owner
Issuer ticker: WHWK
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2026, 19:40:47 UTC
Prior SEC filing: 14 Sep 2023
Source filing: View source filing
Reporting owner signature: Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer

Key filing fact

Avoro Capital Advisors LLC filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 14 May 2026.

Key facts

This page summarizes Avoro Capital Advisors LLC's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 14 May 2026, 19:40.

Change

Previous filing in this sequence was filed on 14 Sep 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001633313 Primary reporting owner

Avoro Capital Advisors LLC

Relationship: Director, Other*, 10%+ Owner
Address: 110 GREENE STREET, SUITE 800, NEW YORK
Signature: Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer
Signature date: 14 May 2026

CIK 0001701815

Aghazadeh Behzad

Relationship: Director, Other*, 10%+ Owner
Address: C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK
Signature: Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer
Signature date: 14 May 2026

CIK 0001879253

Avoro Ventures LLC

Relationship: Director, Other*, 10%+ Owner
Address: 110 GREEN STREET, SUITE 800, NEW YORK
Signature: /s/ Behzad Aghazadeh
Signature date: 14 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Pre-funded Warrant (right to buy)

Award

Transaction value
Shares: +6,377,714
Change %: +77%
Price: $3.92^*
Shares after: 14,710,714
Date: 12 May 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 6,377,714
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4

WHWK transaction Derivative

Pre-funded Warrant (right to buy)

Award

Transaction value
Shares: +6,377,714
Change %: +77%
Price: $3.92^*
Shares after: 14,710,714
Date: 12 May 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 6,377,714
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4

WHWK transaction Derivative

Pre-funded Warrant (right to buy)

Award

Transaction value
Shares: +6,377,714
Change %: +77%
Price: $3.92^*
Shares after: 14,710,714
Date: 12 May 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 6,377,714
Exercise price: $0.000100
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors (as defined below) directly from the Issuer in a private placement.

Footnote F2

Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after May 12, 2026, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the "19.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker.

Footnote F3

This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures.

Footnote F4

The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

SEC remarks

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.